Preparation, in vitro release and antibacterial activity evaluation of rifampicin and moxifloxacin-loaded poly(D,L-lactide-co-glycolide) microspheres
Source abstract
Abstract
Osteomyelitis is difficult to treat because infective bone is poorly accessible for intravenously administering antibiotics and biofilm formation increases bacterial resistance. In this study, microspheres prepared using poly(lactide-co-glycolide) (PLGA) and embedded with moxifloxacin (MOX-PLGA microspheres) and rifampicin/moxifloxacin (RIF/MOX-PLGA microspheres) using the water-in-oil-in-water double emulsion solvent evaporation technique were used for local delivery. Shape of MOX-PLGA microspheres and RIF/MOX-PLGA microspheres were spherical, mean particle size of them were 20.52 μm and 16.62 μm, respectively. Encapsulation efficiency of the MOX-PLGA microspheres was 17.35% ± 2.42%. However, the encapsulation efficiency for MOX and RIF in RIF/MOX-PLGA microspheres was 33.25% ± 7.51% and 49.0% ± 11.25%, respectively. Moxifloxacin and rifampicin were released slowly from microspheres. Both microspheres can efficiently release antibiotics in vitro. Antibacterial and bacterial biofilm-inhibition properties of the released solution were investigated from RIF/MOX-PLGA, MOX-PLGA, and blank PLGA microspheres at varying time points in vitro. RIF/MOX-PLGA microspheres demonstrated the strongest antibacterial activity and bacterial biofilm-inhibition property than the other two microspheres (p < .05). This study suggests that the novel RIF/MOX-PLGA microspheres can be used as a promising carrier for osteomyelitis treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Orthopedic Infections and Treatments · Antimicrobial agents and applications · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedics, Xijing Hospital, Fourth Military Medical University
Department of Orthopedics, General Hospital of Ningxia Medical University
Department of Pharmacy, Institute of Clinical Pharmacology, General Hospital of Ningxia Medical University
General Hospital of Ningxia Medical University
Affiliated General Hospital, Ningxia Medical University
Funding
the Nature Science Foundation of Ningxia Province
References (42)
Show source-provided references
1. 10.1016/j.jconrel.2015.04.02210.1016/j.jconrel.2015.04.022 ↗
2. 10.1016/j.mehy.2017.06.02310.1016/j.mehy.2017.06.023 ↗
3. 10.1016/j.jor.2016.10.00410.1016/j.jor.2016.10.004 ↗
4. 10.1111/joim.1223310.1111/joim.12233 ↗
5. 10.1016/j.biomaterials.2015.12.01210.1016/j.biomaterials.2015.12.012 ↗
6. 10.1016/j.msec.2014.04.05510.1016/j.msec.2014.04.055 ↗
7. 10.1128/CMR.00134-1410.1128/CMR.00134-14 ↗
8. 10.3389/fmicb.2018.0258310.3389/fmicb.2018.02583 ↗
9. 10.1016/j.biotechadv.2016.09.00510.1016/j.biotechadv.2016.09.005 ↗
10. 10.1021/acsami.6b1491210.1021/acsami.6b14912 ↗
11. 10.1177/088532821662982310.1177/0885328216629823 ↗
12. 10.1016/j.actbio.2016.11.02810.1016/j.actbio.2016.11.028 ↗
13. 10.3109/21691401.2016.116163710.3109/21691401.2016.1161637 ↗
14. 10.1016/j.colsurfb.2017.07.03810.1016/j.colsurfb.2017.07.038 ↗
15. 10.3233/BME-17170310.3233/BME-171703 ↗
16. 10.1016/j.actbio.2014.06.01310.1016/j.actbio.2014.06.013 ↗
17. 10.1016/j.injury.2017.08.02110.1016/j.injury.2017.08.021 ↗
18. 10.1128/AAC.01822-1610.1128/AAC.01822-16 ↗
19. 10.1093/femspd/ftw01910.1093/femspd/ftw019 ↗
20. 10.1586/14787210.2015.99966910.1586/14787210.2015.999669 ↗
21. 10.1007/s00264-015-2819-210.1007/s00264-015-2819-2 ↗
22. 10.1016/j.ijantimicag.2017.01.04110.1016/j.ijantimicag.2017.01.041 ↗
23. Posadowska U, Brzychczy-Włoch M, Pamuła E, et al. Gentamicin loaded PLGA nanoparticles as local drug delivery system for the osteomyelitis treatment. Acta Bioeng Biomech. 2015;17:41–48.
24. 10.1007/s11095-012-0803-810.1007/s11095-012-0803-8 ↗
25. Visani J, Staals EL, Donati D. Treatment of chronic osteomyelitis with antibiotic-loaded bone void filler systems: an experience with hydroxyapatites calcium-sulfate biomaterials. Acta Orthop Belg. 2018;84:25–29.
26. 10.1007/s11095-017-2212-510.1007/s11095-017-2212-5 ↗
27. 10.1021/acsnano.6b0008710.1021/acsnano.6b00087 ↗
28. 10.1080/21691401.2016.123311010.1080/21691401.2016.1233110 ↗
29. 10.2147/DDDT.S13851010.2147/DDDT.S138510 ↗
30. 10.1016/j.jconrel.2012.03.02710.1016/j.jconrel.2012.03.027 ↗
31. 10.1007/s13346-016-0278-y10.1007/s13346-016-0278-y ↗
32. 10.1016/j.ijpharm.2016.01.02010.1016/j.ijpharm.2016.01.020 ↗
33. 10.1016/j.actbio.2010.12.01410.1016/j.actbio.2010.12.014 ↗
34. 10.1007/s10266-014-0187-910.1007/s10266-014-0187-9 ↗
35. 10.1016/j.msec.2015.09.05310.1016/j.msec.2015.09.053 ↗
36. 10.1016/j.biomaterials.2015.02.02010.1016/j.biomaterials.2015.02.020 ↗
37. 10.1093/jac/dkv37110.1093/jac/dkv371 ↗
38. 10.1016/j.actbio.2018.04.02410.1016/j.actbio.2018.04.024 ↗
39. 10.3390/ijms1208503910.3390/ijms12085039 ↗
40. 10.1016/j.ijantimicag.2014.11.01110.1016/j.ijantimicag.2014.11.011 ↗
41. 10.2147/DDDT.S13888810.2147/DDDT.S138888 ↗
42. 10.1002/jor.2319410.1002/jor.23194 ↗